Alpha Cognition Inc
ACOG
Peringkat dalam Saham
#20189
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Harga Saham
$8.47
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$131.47M
Perubahan (1 hari)
3.36%
Perubahan (1 tahun)
68.29%
Negara
US
Perdagangan Alpha Cognition Inc (ACOG)
Kategori
Healthcare
Laba untuk Alpha Cognition Inc (ACOG)
Laba pada Jun 2026 TTM: 0.00
Menurut laporan keuangan terbaru dari Alpha Cognition Inc, laba saat ini perusahaan adalah 0.00. Pada tahun 2022, perusahaan memperoleh laba sebesar $-12.11M, peningkatan dibandingkan laba tahun 2021 sebesar $-19.55M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Alpha Cognition Inc dari 2018 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2023 | $-13.77M | 13.68% |
| 2022 | $-12.11M | -38.02% |
| 2021 | $-19.55M | 237.90% |
| 2020 | $-5.78M | -12.45% |
| 2019 | $-6.61M | 20,254.71% |
| 2018 | $-32.46K | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
